Recombinant virus vaccination against 'self' antigens using anchor- fixed immunogens

Kari R. Irvine, Maria R. Parkhurst, Eliza P. Shulman, Janis P. Tupesis, Mary Custer, Christopher E. Touloukian, Paul F. Robbins, Alicia Gómez Yafal, Patricia Greenhalgh, Roger P.M. Sutmuller, Rienk Offringa, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


To study the induction of anti-'self' CD8+ T-cell reactivity against the tumor antigen gp100, we used a mouse transgenic for a chimeric HLAA*0201/H-2 Kb molecule (A2/K(b)). We immunized the mice with a recombinant vaccinia virus encoding a form of gp100 that had been modified at position 210 (from a threonine to a methionine) to increase epitope binding to the restricting class I molecule. Immunogens containing the 'anchor- fixed' modification elicited anti-self CD8+ T cells specific for the wild- type gp100209-217 peptide pulsed onto target cells. More important, these cells specifically recognized the naturally presented epitope on the surface of an A2/Kb-expressing murine melanoma, B16. These data indicate that anchor-fixing epitopes could enhance the function of recombinant virus- based immunogens.

Original languageEnglish (US)
Pages (from-to)2536-2540
Number of pages5
JournalCancer Research
Issue number11
StatePublished - Jun 1 1999
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Recombinant virus vaccination against 'self' antigens using anchor- fixed immunogens'. Together they form a unique fingerprint.

Cite this